TORONTO, July 21 /CNW/ - Biosign Technologies Inc. (the "Company",
"Biosign") (CNQ: BIOS) announced today the appointment of Chris Butlin as
chief technology officer (CTO), effective August 5, 2008.
Chris Butlin has a Ph.D. in Control Engineering from the Imperial
College, University of London. He brings to Biosign over twenty-five years
experience across a variety of industries, including Life Sciences, Aerospace,
Information Systems, and Electronics Industries.
As General Manager and VP Engineering for the Molecular Diagnostics
Division of Bayer Inc in Toronto, Chris was responsible for all design,
manufacture, and marketing of the Trugene DNA Sequencing System.
As Director of Corporate Engineering for MacDonald-Dettwiler and
Associates of Vancouver B.C., he provided information system leadership to the
engineering and R&D functions of the corporate facility and its subsidiaries.
As Biosign's CTO, Butlin will play a key leadership role in realizing
Biosign's strategy and vision. He will work closely with the marketing team
and report to the president and chief executive officer, Radu Leca.
For further information:
For further information: Radu Leca, President & CEO, Biosign
Technologies Inc., Phone: (416) 218-9800 ext. 222, Email: email@example.com